Incyte axes JAK1 inhibitor from pipeline two years after a PhIII flop crushed hopes
In the first few days of 2020, Incyte reported that its JAK1 inhibitor failed a Phase III study in first-line, acute graft vs host disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
